In a groundbreaking clinical development reported by the Cleveland Clinic, a single experimental dose of CRISPR-based gene therapy has successfully reduced LDL (“bad”) cholesterol and triglycerides by approximately 50% in patients with severe, difficult-to-treat lipid disorders. Remarkably, follow-up data confirms that these massive reductions remained fully stable one year after administration, with the highest dosage cohort showing a 52.5% reduction in LDL. This marks a paradigm shift from daily medications to one-time permanent molecular interventions for cardiovascular disease prevention.
About the Author
